Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Dihedral - D2  (3D View)
Global Stoichiometry: Homo 4-mer - A4 

Biological assembly 1 generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 192272.95 
• Atom Count: 12553 
• Residue Count: 1764 
• Unique protein chains: 1

3BGL

Hepatoselectivity of Statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors

• DOI: 10.2210/pdb3BGL/pdb

• Classification: OXIDOREDUCTASE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): 1 


• Deposited: 2007-11-26 Released: 2008-01-29 
• Deposition Author(s): Finzel, B.C., Pavlovsky, A., Park, W.K.C.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.225 Å
• R-Value Free: 0.251 
• R-Value Work: 0.208 

Literature

Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.

Park, W.K., Kennedy, R.M., Larsen, S.D., Miller, S., Roth, B.D., Song, Y., Steinbaugh, B.A., Sun, K., Tait, B.D., Kowala, M.C., Trivedi, B.K., Auerbach, B., Askew, V., Dillon, L., Hanselman, J.C., Lin, Z., Lu, G.H., Robertson, A., Sekerke, C.

(2008) Bioorg.Med.Chem.Lett. 18: 1151-1156

• PubMed: 18155906 
• DOI: 10.1016/j.bmcl.2007.11.124


• PubMed Abstract: 
  

4-Sulfamoyl pyrroles were designed as novel hepatoselective HMG-CoA reductase inhibitors (statins) to reduce myalgia, a statin-induced adverse effect. The compounds were prepared via a [3+2] cycloaddition of a Münchnone with a sulfonamide-substituted alkyne. We identified compounds with greater selectivity for hepatocytes compared to L6-myocytes than rosuvastatin and atorvastatin. There was an inverse correlation of myocyte potencies and ClogP values. A number of analogs were effective at reducing cholesterol in acute and chronic in vivo models but they lacked sufficient chronic in vivo activity to warrant further development.

---

Organizational Affiliation: 

Department of Chemistry, CVMED, Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI, USA. [e-mail]

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
3-hydroxy-3-methylglutaryl-coenzyme A reductase	A, B, C, D	441	Homo sapiens	Mutation(s): 1  Gene Names: HMGCR EC: 1.1.1.34
Find proteins for P04035 (Homo sapiens) Go to Gene View: HMGCR Go to UniProtKB:  P04035

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
RID	A, B, C, D	(3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-4-(morpholin-4-ylsulfonyl)-3-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid C30 H37 F N2 O7 S XLVZRBHNHHAPDT-JWQCQUIFSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
RID	IC50: 4.5 nM BINDINGMOAD
RID	IC50: 4.5 nM PDBBIND

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.225 Å
• R-Value Free: 0.251 
• R-Value Work: 0.208 
• Space Group: P 1 2₁ 1

Unit Cell:

Length (Å)	Angle (°)
a = 71.588	α = 90.00
b = 172.156	β = 117.24
c = 75.148	γ = 90.00

Software Package:

Software Name	Purpose
REFMAC	refinement
HKL-2000	data scaling
DENZO	data reduction
PDB_EXTRACT	data extraction
SCALEPACK	data scaling
HKL-2000	data reduction

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2007-11-26 
• Released Date: 2008-01-29 
• Deposition Author(s): Finzel, B.C., Pavlovsky, A., Park, W.K.C.

Revision History 

• Version 1.0: 2008-01-29
  Type: Initial release
• Version 1.1: 2011-07-13
  Type: Version format compliance
• Version 1.2: 2017-10-25
  Type: Refinement description